MYL

Mylan's Dey L.P. Announces Establishment of 'J-Code' for Perforomist(TM) Inhalation Solution - 11/06 - 08:45 AM ET

Mylan Inc announces receipt of final FDA approval for Levetiracetam Tablets - 11/05 - 07:53 AM ET

Mylan Launches Generic Version Of Epilepsy Drug Keppra After FDA Approval - 11/04 - 09:07 PM ET

Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately - 11/04 - 12:48 PM ET

MYL: Q3 Earnings Call @ 10:00 ET Today [delayed] - 10/30 - 07:38 AM ET

Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 - 10/30 - 07:30 AM ET

Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI - 10/29 - 01:00 PM ET

New Data on Perforomist(TM) Inhalation Solution to be Presented at CHEST 2008 - 10/24 - 11:18 AM ET

Mylan Schedules Third Quarter Financial Results Conference Call and Live Webcast - 10/16 - 08:00 AM ET

Mylan Announces $500 Million of Floating Rate Debt Swapped to Fixed Rates - 10/09 - 07:30 AM ET

Mylan Inc announces FDA approval for generic Risperdal Tablets - 09/17 - 05:09 AM ET

Mylan Inc closes offering of cash convertible note due 2015 - 09/16 - 05:12 AM ET

Mylan Sells $575 Million Of Convertible Notes - 09/15 - 11:47 PM ET

Mylan Completes $575 Million Cash Convertible Note Offering, Including Exercise of Overallotment Option - 09/15 - 04:30 PM ET

Mylan Prices $500 Million Of Convertible Notes - 09/10 - 04:05 PM ET

Mylan Prices $500 Million Cash Convertible Notes due 2015 - 09/10 - 07:00 AM ET

Mylan Laboratories (MYL) NewsBite - Mylan to Offer $400M in Notes - 09/09 - 10:45 AM ET

Mylan Drops During Pre-Market Trading - 09/09 - 09:17 AM ET

Mylan To Retain Specialty Pharmaceutical Unit Dey LP - 09/09 - 01:05 AM ET

Mylan to Offer $400 Million in Cash Convertible Notes - 09/08 - 05:28 PM ET

Page 1 of 6     1  2   3   4   5   >   >>|     Previous  |  Next

<< Back to Stock Index